Targeted Drug Delivery

animated video

EDV mediated drug delivery
EnGeneIC has invented methods by which a range of different chemotherapeutic drugs (cytotoxic as well as molecularly targeted) e.g. Doxorubicin, Paclitaxel, Carboplatin, etc can be readily packaged within the EDVs. EDVs can then be targeted to a specific cancer cell by attachment of a bispecific antibody. One end of the bispecific antibody attaches to the EDV and the other end is available for binding to a surface receptor expressed by the cancer cell. Once delivered inside the cell via endocytosis the EDVs are broken down in the late endosomes and the chemotherapeutic drugs released into the cytoplasm, where they are taken up by the nucleus. The drugs have been shown to remain bioactive and to be cytotoxic to the targeted cells. This process is shown schematically illustration above

Human tumour xenografts in mice treated with
drug-packaged, bispecific antibody-targeted EDVs

In-vivo therapeutic efficacy of bispecific antibody-targeted, drug-packaged EDVs has been evaluated in several human tumor xenograft experiments in mice.
These results are described in the three published papers. Essentially, all EDV-based therapeutics tested in different human tumor xenografts gave rise to a dramatic anti-tumor effects compared to various control treatments and many of these resulted in 100% survival of the mice treated with specifically-targeted, drug-packaged EDVs.